Autopsy report · NCT00607399
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 46 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- SGX Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Advanced Cancer
- Interventions
- SGX523 Capsules
- Participants
- 46 (planned, not actual)
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.